Elekta operates through four core product lines: Oncology (linear accelerators and imaging systems), Brachytherapy (internal radiation treatment), Neuroscience (neurological diagnosis and treatment), and Software (clinical workflow and treatment planning solutions). The company is undergoing strategic restructuring with 450-employee reduction targeting over SEK 500 million in annual cost savings while managing near-term headwinds in key markets like China and FX pressures.
Cyborg Score Rationale
Elekta maintains a strong market position in specialized medical technology with stable revenue around SEK 18 billion and established global distribution. However, recent strategic challenges including market volatility in China, FX headwinds, earnings decline of 82% YoY, and significant order book adjustments indicate execution risk and near-term uncertainty despite long-term market fundamentals.
Top Insights
Strategic restructuring: 450 employees being reduced with SEK 500M+ annual cost savings starting Q1 2026/27 as company simplifies organizational structure
Order book quality initiative: SEK 2.2 billion order cancellation from firmer interpretation of criteria to improve predictability and profitability with no revenue impact
Geographic challenges: China sales recovery expected only in H2 2025/26; FX headwinds and tariffs continue impacting earnings guidance
Capital allocation: Company paying SEK 2.40 per share dividend (two SEK 1.20 payments) demonstrating shareholder confidence despite operational challenges
Named Competitors
Radiation Therapy Systems — Diversified healthcare equipment and imaging solutions
Orthopedic & Surgical Equipment — Medical device manufacturer with broad surgical portfolio
Medical Device Solutions — Specialized surgical and oncology equipment
Recent Developments
(January 2026) Strategic Update announced focusing on growth initiatives and organizational restructuring with cost reduction targets
(November 2025) Q2 2025/26 results showed 6.2% revenue decline YoY to SEK 4.07B; order book review completed with SEK 2.2B adjustments
(September 2025) Annual General Meeting held with dividend approval and board governance updates
Open the full interactive Elekta AB report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.